Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

European Journal of Haematology

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Clinical Pharmacology and Therapeutics

A novel two-part mixture model for the incidence and time course of cytokine release syndrome after elranatamab dosing in multiple myeloma patients

Transfusion Clinique et Biologique

Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma

Blood and Lymphatic Cancer: Targets and Therapy

The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: A comprehensive review

Leukemia & Lymphoma

Are we maintaining minimal residual disease in myeloma?